MM
Mimetic Medicines develops short lipidated peptidomimetics (SLiPs) designed to disrupt ion channel-scaffold protein complexes in peripheral pain nerves. These SLiPs selectively target nociceptors responsible for neuropathic pain signaling without crossing the blood-brain barrier. This mechanism offers a potentially disease-modifying approach to pain management with improved safety and tolerability compared to current CNS-acting therapies.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Mimetic Medicines develops short lipidated peptidomimetics (SLiPs) designed to disrupt ion channel-scaffold protein complexes in peripheral pain nerves. These SLiPs selectively target nociceptors responsible for neuropathic pain signaling without crossing the blood-brain barrier. This mechanism offers a potentially disease-modifying approach to pain management with improved safety and tolerability compared to current CNS-acting therapies.